We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
Notice for Donidalorsen (Otsuka Australia Pharmaceutical Pty Ltd)
Active ingredients
Donidalorsen
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
solution for injection for subcutaneous injection
Indication
For the routine prevention of recurrent attacks of hereditary angioedema (HAE)
Therapeutic area
Immunology